👋
Is this profile yours? Take control to keep your details current, set fees, and respond to reviews.
This page is aggregated from public sources.
Claim this profile →
✓ Verified
Trust score 98/100
Accepting new patients
Dr
Dr Ami Sabharwal
Oncology
English
2,985+
Patients seen
14
Years in practice
11
Publications
1
Languages spoken
About
Dr. Ami Sabharwal is a consultant oncologist with a special clinical interest in non-surgical management of prostate and bladder cancers using advanced radiotherapy techniques, brachytherapy, hormone therapies, drug therapies and radionucleotides.
Dr Sabharwal trained in London and Oxford, becoming a Consultant Oncologist in Oxford in 2009; giving her a wealth of experience as a consultant over the last 12 years treating patients with excellent outcomes.
Ami has a specialist interest in treating urological cancers, primarily with targeted radiotherapy (IMRT and IGRT), as well as low dose rate brachytherapy and with systemic agents (hormones, chemotherapy, biological and radionucleotide therapies). She is an advocate for patient centred care (clear communication, patient choice and informed consent), understanding the need for individualised treatment.
Dr. Sabharwal is active in the field of research, acting as Principle Investigator in a a number of Phase 3 clinical trials. She was Governance lead (2010-19) for Oncology (including Radiotherapy) and in addition Oncology Morbidity and Mortality chair at the Oxford University Hospitals NHS Foundation Trust.
Diseases, Medical Tests and Treatments
• Intensity modulated radiotherapy (IMRT)
• Image guided radiotherapy (IGRT)
• Radiotherapy
• Brachytherapy (ARSAC holder for Iodine-125)
• Chemotherapy
• Immunotherapy
• Hormone therapy
• Radionucleotides (ARSAC holder for Radium-223)
• Prostate Cancer
• Bladder Cancer
Dr Sabharwal trained in London and Oxford, becoming a Consultant Oncologist in Oxford in 2009; giving her a wealth of experience as a consultant over the last 12 years treating patients with excellent outcomes.
Ami has a specialist interest in treating urological cancers, primarily with targeted radiotherapy (IMRT and IGRT), as well as low dose rate brachytherapy and with systemic agents (hormones, chemotherapy, biological and radionucleotide therapies). She is an advocate for patient centred care (clear communication, patient choice and informed consent), understanding the need for individualised treatment.
Dr. Sabharwal is active in the field of research, acting as Principle Investigator in a a number of Phase 3 clinical trials. She was Governance lead (2010-19) for Oncology (including Radiotherapy) and in addition Oncology Morbidity and Mortality chair at the Oxford University Hospitals NHS Foundation Trust.
Diseases, Medical Tests and Treatments
• Intensity modulated radiotherapy (IMRT)
• Image guided radiotherapy (IGRT)
• Radiotherapy
• Brachytherapy (ARSAC holder for Iodine-125)
• Chemotherapy
• Immunotherapy
• Hormone therapy
• Radionucleotides (ARSAC holder for Radium-223)
• Prostate Cancer
• Bladder Cancer
“Evidence-based care tailored to each patient — taking the time to explain options and shared decisions.”
— Dr Ami Sabharwal
Education & training
-
2002–2008 MD · Medicine and Surgery
-
2008–2012 Residency · Oncology
-
2012–2013 Fellowship · Subspecialty training
Career & appointments
-
2012-09–2013-08 Junior consultant
Licenses & insurance
Medical licenses
GB — Organización Médica Colegial de España (OMC)
Board certifications
European Board of Oncology
Malpractice insurance:
HDI Global · 4,000,000 EUR coverage
· No claims on file
Procedures performed
| Procedure | Code | Lifetime count |
|---|---|---|
| GP consultation | 99213 | 1,912 |
| Annual physical exam | 99395 | 2,646 |
| Vaccination administration | 90471 | 622 |
| Minor procedure (skin) | 17110 | 3,009 |
Services & pricing
| Service | Duration | Modality | Price |
|---|---|---|---|
| New patient consultation (60m) | 60 min | in_clinic|telemed | 180.00 EUR |
| Follow-up consultation (30m) | 30 min | in_clinic|telemed|phone | 90.00 EUR |
| Vaccination administration | 60 min | in_clinic | 810.00 EUR |
| Minor procedure (skin) | 90 min | in_clinic | 540.00 EUR |
Office, team & in practice
Videos
Research & publications
h-index: 3 · i10: 7
-
European registry analysis of Oncology outcomes
DOI: 10.3506/euroclin.2025.0 · PMID: 34685907 · cited by 144
-
Outcomes of Oncology in adults — a multi-centre cohort
DOI: 10.1759/euroclin.2024.1 · PMID: 33294696 · cited by 2
Invited talks
- Practical updates in Oncology European Annual Congress (Oncology) · Vienna · 2024 · invited
- Single-centre experience in Oncology National Society Meeting · · 2023 · oral abstract
Awards & memberships
Awards
- 🏆 Top-rated Oncology — · EuroClinics Patient Choice · 2025 · regional
- 🏆 Excellence in Patient Care · National Society · 2024 · national
Society memberships
- WONCA Europe — Family Doctors — Member · since 2013
- national college of family doctors — Member · since 2013
- European Union of Medical Specialists (UEMS) — Member · since 2013
Patient reviews
- Bedside Manner
- 5.00
- Knowledge
- 5.00
- Wait Time
- 4.75
- Staff Friendliness
- 5.00
- Ease Of Appointment
- 4.90
- Value For Money
- 4.92
- Would Recommend Pct
- 99
-
★ 5 verified visit
“Very thorough first visit — explained every step. Booking was easy and the staff were welcoming.”
-
★ 5 verified visit
“Took time to listen and reviewed all my previous results. I would absolutely recommend.”
-
★ 4 verified visit
“Professional and knowledgeable. Wait on the day was a bit long, otherwise excellent.”
Articles by this doctor
- Patient education Patient guide to Oncology
- Awareness When should you see a oncology?
For international patients
- Coordinator
- Patient liaison · ami.sabharwal@euroclinics.example
- Accepted intl insurance
- Allianz Worldwide · AXA Global · BUPA Global · Cigna Global
